[A19-42] Fingolimod (multiple sclerosis in children and adolescents) - Addendum to Commission A18-87

Last updated 21.06.2019

Project no.:
A19-42

Commission:
Commission awarded on 06.05.2019 by the Federal Joint Committee (G-BA).

Report type:
Addendum

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Head and nerves

Indication:

Children and adolescents with highly active or rapidly evolving relapsing-remitting multiple sclerosis (RRMS)

Result of dossier assessment:

In one research question now also hint of added benefit in the category "health-related quality of life"; conclusion of dossier assessment A18-87 nonetheless unchanged

Note:

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

21.06.2019

Fingolimod: advantages for children and adolescents with highly active RRMS requiring treatment switch

Subsequently submitted data on quality of life are informative / added benefit in one of four patient groups

Accompanying information

Further information for consumers and patients is provided on IQWiG's health information website www.informedhealth.org.

Federal Joint Committee (G-BA)

2019-06-20 A G-BA decision was published.

G-BA documents on this decision

Contact

Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.